The clinical pharmacology of buprenorphine: Extrapolating from the laboratory to the clinic

Drug and Alcohol Dependence

Volumn 70, Issue 2 SUPPL., 2003, Pages

  Walsh, Sharon L ^a   Eissenberg, Thomas ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Buprenorphine; Clinical pharmacology; Humans; Naloxone; Opioid; Review

Indexed keywords

BUPRENORPHINE; BUPRENORPHINE PLUS NALOXONE; CLONIDINE; DIAMORPHINE; HYDROMORPHONE; LEVACETYLMETHADOL; METHADONE; MORPHINE; MU OPIATE RECEPTOR AGONIST; NALOXONE; OPIATE AGONIST; UNCLASSIFIED DRUG;

ACUTE DRUG ADMINISTRATION; BACKACHE; BEHAVIOR DISORDER; BINDING AFFINITY; CHRONIC DRUG ADMINISTRATION; CLINICAL PHARMACOLOGY; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG ABUSE; DRUG APPROVAL; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CROSS TOLERANCE; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MISUSE; DRUG OVERDOSE; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; DYSPHORIA; GASTROINTESTINAL MOTILITY; HEROIN DEPENDENCE; HOT FLUSH; HUMAN; INTOXICATION; IRRITABILITY; LETHARGY; LONG TERM EXPOSURE; LOW DRUG DOSE; NAUSEA; NONHUMAN; OPIATE ADDICTION; PRIORITY JOURNAL; RESPIRATION DEPRESSION; RESTLESSNESS; REVIEW; SIDE EFFECT; TABLET FORMULATION; URINE RETENTION; WITHDRAWAL SYNDROME;

EID: 0037987962     PISSN: 03768716     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0376-8716(03)00056-5     Document Type: Review

References (82)

1. Amass L., Bickel W.K., Higgins S.T., Badger G.J. Alternate-day dosing during buprenorphine treatment of opioid dependence. Life Sci. 54:1994;1215-1228.
2. Amass L., Bickel W.K., Crean J.P., Blake J., Higgins S.T. Alternate-day buprenorphine dosing is preferred to daily dosing by opioid-dependent humans. Psychopharmacology. 136:1998;217-225.
3. Ariens E.J. Intrinsic activity: partial agonists and partial antagonists. J. Cardiovasc. Pharmacol. 5:1983;S8-15.
4. Bedi N.S., Ray R., Jain R., Dhar N.K. Abuse liability of buprenorphine: a study among experienced drug users. Indian J. Physiol. Pharmacol. 42:1998;95-100.
5. Berkowitz B.A., Ngai S.H., Hempstead J., Spector S. Disposition of naloxone: use of a new radioimmunoassay. J. Pharmacol. Exp. Ther. 195:1975;499-504.
6. Bickel W.K., Stitzer M.L., Bigelow G.E., Liebson I.A., Jasinski D.R., Johnson R.E. Buprenorphine: dose-related blockade of opioid challenge effects in opioid dependent humans. J. Pharmacol. Exp. Ther. 247:1988;47-53.
7. Bickel W.K., Amass L., Crean J.P., Badger G. Buprenorphine dosing every 1, 2 or 3 days in opioid-dependent patients. Psychopharmacology. 146:1999;111-118.
8. Blom Y., Bondesson U., Gunne L.M. Effects of buprenorphine in heroin addicts. Drug Alcohol Depend. 20:1987;1-7.
9. Cheskin L.J., Fudala P.J., Johnson R.E. A controlled comparison of buprenorphine and clonidine for acute detoxification of opioids. Drug Alcohol Depend. 36:1994;115-121.
10. Clark N.C., Lintzeris N., Muhlesisen P.J. Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose. Med. J. Aust. 176:2002;166-167.
11. Comer S.D., Collins E.D., Fischman M.W. Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. Psychopharmacology. 154:2001;28-37.
12. Comer S.D., Collins E.D., Fischman M.W. Intravenous buprenorphine self-administration by detoxified heroin abusers. J. Pharmacol. Exp. Ther. 301:2002;266-276.
13. Cowan A., Lewis J.W., MacFarlane I.R. Agonist and antagonist properties of buprenorphine: a new antinociceptive agent. Br. J. Pharmacol. 60:1977;537-545.
14. Cowan A., Doxey J.C., Harry E.J.R. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br. J. Pharmacol. 60:1977;547-554.
15. Dole V.P., Nyswander M.E., Kreek M.J. Narcotic blockade. Arch. Intern. Med. 118:1966;304-309.
16. Dum J.E., Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonist and antagonistic actions. Br. J. Pharmacol. 74:1981;627-633.
17. Eissenberg T., Greenwald M.K., Johnson R.E., Liebson I.A., Bigelow G.E., Stitzer M.L. Buprenorphine's physical dependence potential: antagonist-precipitated withdrawal in humans. J. Pharmacol. Exp. Ther. 276:1996;449-459.
18. Eissenberg T.R., Johnson R.E., Bigelow G.E., Walsh S.L., Liebson I.A., Strain E.C., Stitzer M.L. Controlled opioid withdrawal evaluation during 72-h dose omission in buprenorphine-maintained patients. Drug Alcohol Depend. 45:1997;81-91.
19. 3H in normal and narcotic-dependent men. J. Pharmacol. Exp. Ther. 187:1973;575-580.
20. Fraser, H.F., Van Horn, G.G., Martin, W.R., Wolbach, A.B., Isbell, H., 1961. Methods for evaluating addiction liability. (A) Attitude of opiate addicts toward opiate-like drugs, (B) A short-term 'direct' addiction test. J. Pharmacol. Exp. Therapeutics 133, 371-378.
21. Fudala P.J., Jaffe J.H., Dax E.M., Johnson R.E. Use of buprenorphine in the treatment of opioid addiction. II. Physiologic and behavioral effects of daily and alternate-day administration and abrupt withdrawal. Clin. Pharmacol. Ther. 47:1990;525-534.
22. Fudala P.J., Yu E., Macfadden W., Boardman C., Chiang C.N. Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts. Drug Alcohol Depend. 50:1998;1-8.
23. Fukase H., Fukuzaki K., Koja T., Nagata R., Lukas S.E. Effects of morphine, naloxone, buprenorphine, butorphanol, haloperidol and imipramine on morphine withdrawal signs in cynomolgus monkeys. Psychopharmacology. 116:1994;396-400.
24. Greenwald M.K., Schuh K.J., Hopper J.A., Schuster C.R., Johanson C.-E. Effects of buprenorphine sublingual tablet maintenance on opioi drug-seeking behavior by humans. Psychopharmacology. 160:2002;344-352.
25. Gross A., Jacobs E.A., Petry N.M., Badger G.J., Bickel W.K. Limits to buprenorphine dosing: a comparison between quintuple and sextuple the maintenance dose every 5 days. Drug Alcohol Depend. 64:2001;111-116.
26. Haertzen C.A. An Overview of Addiction Research Center Inventory Scales (ARCI): An Appendix and Manual of Scales. 1974;National Institute on Drug Abuse, Rockville, MD. DHEW Publication No. (ADM) 74-92.
27. Hambrook J.M., Rance M.J. The interaction of buprenorphine with the opiate receptor: lipophilicity as a determining factor in drug-receptor kinetics. Kosterlitz H.W. Opiates and Endogenous Opioid Peptides. 1976;295-301 Biomedical Press, Elsevier/North Holland, Amsterdam.
28. Hughes C.E., Picker M.J., Dykstra L.A. Tolerance and cross-tolerance to the response rate-decreasing effects of μ opioids in morphine-maintained squirrel monkeys. Behav. Pharmacol. 6:1995;776-784.
29. Jaffe J.H., Schuster C.R., Smith B.B., Blachly P.H. Comparison of acetylmethadol and methadone in the treatment of long-term heroin users: a pilot study. J. Am. Med. Assoc. 211:1970;1834-1836.
30. Jasinski D.R., Pevnick J.S., Griffith J.D. Human pharmacology and abuse potential of the analgesic buprenorphine. Arch. Gen. Psychiatry. 35:1978;501-506.
31. Jasinski D.R., Boren J.J., Henningfield J.E., Johnson R.E., Lange W.R., Lukas S.E. Progress report from the NIDA Addiction Research Center, Baltimore, MD. NIDA Res. Mongr. 49:1984;69-76.
32. Jasinski D.R., Fudala P.J., Johnson R.E. Sublingual versus subcutaneous buprenorphine in opiate abusers. Clin. Pharmacol. Ther. 5:1989;513-519.
33. Johnson S.M., Fleming W.W. Mechanisms of cellular adaptive sensitivity changes: applications to opioid tolerance and dependence. Pharmacol. Rev. 41:1989;435-488.
34. Johnson R.E., Cone E.J., Henningfield J.E., Fudala P.J. Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction. Clin. Pharmacol. Ther. 46:1989;335-343.
35. Johnson R.E., Fudala P.J., Jaffe J.H. A controlled trial of buprenorphine for opioid dependence. J. Am. Med. Assoc. 267:1992;2750-2755.
36. Johnson R.E., Eissenberg T., Stitzer M.L., Strain E.C., Liebson I.A., Bigelow G.E. Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend. 40:1995;27-35.
37. Kintz P. Deaths involving buprenorphine: a compendium of French cases. Forensic Sci. Int. 121:2001;65-69.
38. Kintz P. Buprenorphine-related deaths. Kintz P., Marquet P. Buprenorphine Therapy of Opiate Addiction. 2002;109-117 Humana Press, Totowa, NJ.
39. Kosten T.R., Krystal J.H., Charney D.S., Price L.H., Morgan C.H., Kleber H.D. Opioid antagonist challenges in buprenorphine maintained patients. Drug Alcohol Depend. 25:1990;73-78.
40. Kosten T.R., Morgan C., Kleber H.D. Treatment of heroin addicts using buprenorphine. Am. J. Drug Alcohol Abuse. 17:1991;119-128.
41. Kosten T.R., Schottenfeld R., Ziedonis D., Falcioni J. Buprenorphine versus methadone maintenance for opioid dependence. J. Nerv. Ment. Dis. 181:1993;358-364.
42. Kuhlman J.J. Jr, Levine B., Johnson R.E., Fudala P.J., Cone E.J. Relationship of plasma buprenorphine and norbuprenorphine to withdrawal symptoms during dose induction, maintenance and withdrawal from sublingual buprenorphine. Addiction. 93:1998;549-559.
43. Lange W.R., Fudala P.J., Dax E.M., Johnson R.E. Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend. 26:1990;19-28.
44. Leander J.D. Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology. 26:1987;1445-1447.
45. Levin F.R., Fischman M.W., Connerney I., Foltin R.W. A protocol to switch high-dose, methadone-maintained subjects to buprenorphine. Am. J. Addict. 6:1997;105-116.
46. Lewis J.W. Buprenorphine. Drug Alcohol Depend. 14:1985;363-372.
47. Ling W., Charuvastra C., Collins J.F., Batki S., Brown L.S. Jr, Kintaudi P., Wesson D.R., McNicholas L., Tusel D.J., Malkerneker U., Renner J.A. Jr, Santos E., Casadonte P., Fye C., Stine S., Wang R.I., Segal D. Buprenorphine maintenance treatment of opiate dependence: a multicenter, randomized clinical trial. Addiction. 93:1998;475-486.
48. Martin W.R., Eades C.G., Thompson J.A., Huppler R.E., Gilbert P.E. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197:1976;517-532.
49. Mello N.K., Mendelson J.H. Buprenorphine suppresses heroin use by heroin addicts. Science. 207:1980;657-659.
50. Mello N.K., Mendelson J.H., Kuehnle J.C. Buprenorphine effects on human heroin self-administration: an operant analysis. J. Pharmacol. Exp. Ther. 223:1982;30-39.
51. Mendelson J., Jones R.T., Fernandez I., Welm S., Melby A.K., Baggott M.J. Buprenorphine and naloxone interactions in opiate-dependent volunteers. Clin. Pharmacol. Ther. 60:1996;105-114.
52. Mendelson J., Jones R.T., Welm S., Brown J., Batki S.L. Buprenorphine and naloxone interactions in methadone maintenance patients. Biol. Psychiatry. 41:1997;1095-1101.
53. Nath R.P., Upton R.A., Everhart E.T., Cheung P., Shwonek P., Jones R.T., Mendelson J.E. Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J. Clin. Pharmacol. 39:1999;619-623.
54. Negus S.S., Picker M.J., Dykstra L.A. Kappa antagonist properties of buprenorphine in non-tolerant and morphine-tolerant rats. Psychopharmacology. 98:1989;141-143.
55. Nigam A.K., Ray R., Tripathi B.M. Buprenorphine in opiate withdrawal: a comparison with clonidine. J. Subst. Abuse Treat. 10:1993;391-394.
56. Nutt D., Jasinski D.R. Methadone-naloxone mixtures for use in methadone maintenance programs. I. An evaluation in man of their pharmacological feasibility. II. Demonstration of acute physical dependence. Clin. Pharmacol. Ther. 15:1974;156-166.
57. O'Connor J.J., Moloney E., Travers R., Campbell A. Buprenorphine abuse among opiate addicts. Br. J. Addict. 83:1988;1085-1087.
58. Petry N.M., Bickel W.K., Badger G.J. A comparison of four buprenorphine dosing regimens using open-dosing procedures: is twice-weekly dosing possible. Addiction. 95:2000;1069-1077.
59. Pickworth W.B., Johnson R.E., Holicky B.A., Cone E.J. Subjective and physiologic effects of intravenous buprenorphine in humans. Clin. Pharmacol. Ther. 53:1993;570-576.
60. Preston K.L., Bigelow G.E., Liebson I.A. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology. 94:1988;484-490.
61. Preston K.L., Bigelow G.E., Liebson I.A. Effects of sublingually given naloxone in opioid-dependent human volunteers. Drug Alcohol Depend. 25:1990;27-34.
62. Reynaud M., Tracqui A., Petit G., Potard D., Courty P. Six deaths linked to misuse of buprenorphine-benzodiazepine combinations. Am. J. Psychiatry. 155:1998;448-449.
63. Rosen M.I., Wallace E.A., McMahon T.J., Pearsall H.R., Woods S.W., Price L.H., Kosten T.R. Buprenorphine: duration of blockade of effects of intramuscular hydromorphone. Drug Alcohol Depend. 35:1994;141-149.
64. San, L., Cami, J., Fernandez, T., Olle, J.M., Peri, J.M., Torrens M., 1992. Assessment and management of opoid withdrawal symptoms in buprenorphine-dependent subjects. Br. J. Addict. 87, 55-62.
65. Schuh K.S., Johanson C.-E. Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend. 56:2001;55-60.
66. Schuh K.J., Walsh S.L., Bigelow G.E., Preston K.L., Stitzer M.L. Buprenorphine, morphine, and naloxone effects during ascending morphine maintenance in humans. J. Pharmacol. Exp. Ther. 278:1996;836-846.
67. Schuh K.S., Walsh S.L., Stitzer M.L. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology. 145:1999;162-174.
68. Singh R.A., Mattoo S.K., Malhotra A., Varma V.K. Cases of buprenorphine abuse in India. Acta Psychiatr. Scand. 86:1992;46-48.
69. Stoller K.B., Bigelow G.E., Walsh S.L., Strain E.C. Effects of buprenorphine/naloxone in opioid-dependent humans. Psychopharmacology. 154:2001;230-242.
70. Strain E.C., Preston K.L., Liebson I.A., Bigelow G.E. Acute effects of buprenorphine, hydromophone and naloxone in methadone-maintained volunteers. J. Pharmacol. Exp. Ther. 261:1992;985-993.
71. Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Comparison of buprenorphine and methadone in the treatment of opioid dependence. Am. J. Psychiatry. 151:1994;1025-1030.
72. Strain E.C., Preston K.L., Liebson I.A., Bigelow G.E. Buprenorphine effects in methadone-maintained volunteers: effects at 2 h after methadone. J. Pharmacol. Exp. Ther. 272:1995;628-638.
73. Strain E.C., Walsh S.L., Preston K.L., Liebson I.A., Bigelow G.E. The effects of buprenorphine in buprenorphine-maintained volunteers. Psychopharmacology. 129:1997;329-338.
74. Strain E.C., Stoller K., Walsh S.L., Bigelow G.E. The effects of buprenorphine and buprenorphine/naloxone tablets in non-dependent opioid abusers. Psychopharmacology. 148:2000;374-383.
75. Strain E.C., Walsh S.L., Bigelow G.E. Blockade of hydromorphone effects by buprenorphine/naloxone and buprenorphine. Psychopharmacology. 159:2002;161-166.
76. Walker E.A., Richardson T.M., Young A.M. Tolerance and cross-tolerance to morphine-like stimulus effects of mu opioids in rats. Psychopharmacology. 133:1997;17-28.
77. Walsh S.L., Gilson S.F., Jasinski D.R., Stapleton J.M., Phillips R.L., Dannals R.F., Schmidt J., Preston K.L., Grayson R., Bigelow G.E., Sullivan J.T., Contoreggi C., London E.D. Buprenorphine reduces cerebral glucose metabolism in polydrug abusers. Neuropsychopharmacology. 10:1994;157-170.
78. Walsh S.L., Preston K.L., Stitzer M.L., Cone E.J., Bigelow G.E. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 55:1994;569-580.
79. Walsh S.L., June H.L., Schuh K.J., Preston K.L., Bigelow G.E., Stitzer M.L. Effects of buprenorphine, methadone in methadone-maintained subjects. Psychopharmacology. 119:1995;268-276.
80. Walsh S.L., Preston K.L., Bigelow G.E., Stitzer M.L. Acute administration of buprenorphine in humans: partial agonist and blockade effects. J. Pharmacol. Exp. Ther. 274:1995;361-372.
81. Weinhold L.L., Preston K.L., Farre M., Liebson I.A., Bigelow G.E. Buprenorphine alone and in combination with naloxone in non-dependent humans. Drug Alcohol Depend. 30:1992;263-274.
82. Zacny J.P., Conley K., Galinkin J. Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J. Pharmacol. Exp. Ther. 282:1997;1187-1197.